Square Pharmaceuticals has proposed a 130 percent cash dividend for the fiscal year 2025-26, reflecting a continued upward trend in the company’s financial performance. The recommendation was made during a board meeting held recently.

The pharmaceutical firm reported a 13 percent increase in sales, reaching Tk 8,606 crore for FY26. Profitability also improved by 18 percent, with net earnings rising to Tk 2,770 crore during the same period. This marks a notable growth compared to previous years, further supported by the company’s consistent dividend payments.

In the three preceding financial years, Square Pharmaceuticals distributed cash dividends of 120 percent, 110 percent, and 105 percent respectively. Earlier payouts included dividends of 100 percent and 60 percent, indicating a steady expansion in shareholder returns.

Established in 1958 under the leadership of the late Samson H Chowdhury, Square Pharmaceuticals is recognized as the largest pharmaceutical company in the country. It has expanded its reach internationally, exporting products to more than 40 countries. The company has expressed intentions to enhance its overseas sales performance by optimizing the use of its existing manufacturing facilities.

Shares of Square Pharmaceuticals have demonstrated relative stability over the past year, with prices fluctuating between Tk 198 and Tk 236. On the day following the dividend announcement, the stock traded at Tk 218, reflecting market confidence in the company’s growth prospects.